Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality

Journal of Immunology

Volumn 177, Issue 3, 2006, Pages 1967-1974

  Osuchowski, Marcin F ^a   Welch, Kathy ^a   Siddiqui, Javed ^a   Remick, Daniel G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EOTAXIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPENSATORY ANTIINFLAMMATORY RESPONSE SYNDROME; CONTROLLED STUDY; CYTOKINE PRODUCTION; EARLY DIAGNOSIS; FEMALE; INFLAMMATION; MEDIATOR RELEASE; MIXED ANTIINFLAMMATORY RESPONSE SYNDROME; MORTALITY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 33746190736     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.3.1967     Document Type: Article

References (61)

1. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348: 1546-1554.
2. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29: 1303-1310.
3. Sands, K. E., D. W. Bates, P. N. Lanken, P. S. Graman, P. L. Hibberd, K. L. Kahn, J. Parsonnet, R. Panzer, E. J. Orav, D. R. Snydman, et al. 1997. Epidemiology of sepsis syndrome in 8 academic medical centers. J. Am. Med. Assoc. 278: 234-240.
4. Ohlsson, K., P. Bjork, M. Bergenfeldt, R. Hageman, and R. C. Thompson. 1990. Interleukin-1 receptor aniagonist reduces mortality from endotoxin shock. Nature 348: 550-552.
5. Beutler, B., I. W. Milsark, and A. C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869-871.
6. Haziot, A., G. W. Rong, X. Y. Lin, J. Silver, and S. M. Goyert. 1995. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J. Immunol. 154: 6529-6532.
7. Ziegler, E. J., J. A. McCutchan, J. Fierer, M. P. Glauser, J. C. Sadoff, H. Douglas, and A. I. Braude. 1982. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307: 1225-1230.
8. Fisher, C. J., Jr., G. J. Slotman, S. M. Opal, J. P. Pribble, R. C. Bone, G. Emmanuel, D. Ng, D. C. Bloedow, and M. A. Catalano. 1994. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. 22: 12-21.
9. Reinhart, K., and W. Karzai. 2001. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29: 121-125.
10. Deans, K. J., M. Haley, C. Natanson, P. Q. Eichacker, and P. C. Minneci. 2005. Novel therapies for sepsis: a review. J. Trauma 58: 867-864.
11. Fisher, C. J., Jr., J. F. Dhainaut, S. M. Opal, J. P. Pribble, R. A. Balk, G. J. Slotman, T. J. Iberti, E. C. Rackow, M. J. Shapiro, R. L. Greenman, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-Ira Sepsis Syndrome Study Group. J. Am. Med. Assoc. 271: 1836-1843.
12. Fisher, C. J., Jr., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334: 1697-1702.
13. Keel, M., and O. Trentz. 2005. Pathophysiology of polytrauma. Injury 36: 691-709.
14. Levy, M. M., M. P. Fink, J. C. Marshall, E. Abraham, D. Angus, D. Cook, J. Cohen, S. M. Opal, J. L. Vincent, and G. Ramsay. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31: 1250-1256.
15. Oberholzer, A., C. Oberholzer, and L. L. Moldawer. 2001. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16: 83-96.
16. Bone, R. C. 1996. Sir Isaac Newton, sepsis: SIRS, and CARS. Crit. Care Med. 24: 1125-1128.
17. Knaus, W. A., F. E. Harrell, Jr., J. F. LaBrecque, D. P. Wagner, J. P. Pribble, E. A. Draper, C. J. Fisher, Jr., and L. Soll. 1996. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-Ira Phase III Sepsis Syndrome Study Group. Crit. Care Med. 24: 46-56.
18. Eichacker, P. Q., C. Parent, A. Kalil, C. Esposito, X. Cui, S. M. Banks, E. P. Gerstenberger, Y. Fitz, R. L. Danner, and C. Natanson. 2002. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166: 1197-1205.
19. Ebong, S., D. Call, J. Nemzek, G. Bolgos, D. Newcomb, and D. Remick. 1999. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect. Immun. 67: 6603-6610.
20. Ebong, S. J., D. R. Call, G. Bolgos, D. E. Newcomb, J. I. Granger, M. O'Reilly, and D. G. Remick. 1999. Immunopathologic responses to non-lethal sepsis. Shock 12: 118-126.
21. Remick, D. G., G. R. Bolgos, J. Siddiqui, J. Shin, and J. A. Nemzek. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17: 463-467.
22. Oberholzer, A., S. M. Souza, S. K. Tschoeke, C. Oberholzer, A. Abouhamze, J. P. Pribble, and L. L. Moldawer. 2005. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 23: 488-493.
23. Remick, D. G. 2003. Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr. Pharm. Des. 9: 75-82.
24. Terregino, C. A., B. L. Lopez, D. J. Karras, A. J. Killian, and G. K. Arnold. 2000. Endogenous mediators in emergency department patients with presumed sepsis: are levels associated with progression to severe sepsis and death? Ann. Emerg. Med. 35: 26-34.
25. Mokart, D., M. Merlin, A. Sannini, J. P. Brun, J. R. Delpero, G. Houvenaeghel, V. Moutardier, and J. L. Blache. 2005. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br. J. Anaesth. 94: 767-773.
26. Liliensiek, B., M. A. Weigand, A. Bierhaus, W. Nicklas, M. Kasper, S. Hofer, J. Plachky, H. J. Grone, F. C. Kurschus, A. M. Schmidt, et al. 2004. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113: 1641-1650.
27. Wesche-Soldato, D. E., C. S. Chung, J. Lomas-Neira, L. A. Doughty, S. H. Gregory, and A. Ayala. 2005. In vivo delivery of caspase 8 or Fas siRNA improves the survival of septic mice. Blood 106: 2295-2301.
28. Wichterman, K. A., A. E. Baue, and I. H. Chaudry. 1980. Sepsis and septic shock-a review of laboratory models and a proposal. J. Surg. Res. 29: 189-201.
29. Osuchowski, M. F., J. Siddiqui, S. Copeland, and D. G. Remick. 2005. Sequential ELISA to profile multiple cytokines from small volumes. J. Immunol. Methods 302: 172-181.
30. Osuchowski, M. F., and D. G. Remick. 2006. The repetitive use of samples to measure multiple cytokines: the sequential ELISA. Methods 38: 304-311.
31. Nemzek, J. A., J. Siddiqui, and D. G. Remick. 2001. Development and optimization of cytokine ELISAs using commercial antibody pairs. J. Immunol. Methods 255: 149-157.
32. Efron, B., and R. Tibshirani. 1993. An Introduction to the Bootstrap. Chapman & Hall, New York.
33. Lasko, T. A., J. G. Bhagwat, K. H. Zou, and L. Ohno-Machado. 2005. The use of receiver operating characteristic curves in biomedical informatics. J. Biomed. Inform. 38: 404-415.
34. Hotchkiss, R. S., and I. E. Karl. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348: 138-150.
35. Newcomb, D., G. Bolgos, L. Green, and D. G. Remick. 1998. Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Shock 10: 110-117.
36. Remick, D. G., D. R. Call, S. J. Ebong, D. E. Newcomb, P. Nybom, J. A. Nemzek, and G. E. Bolgos. 2001. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit. Care Med. 29: 473-481.
37. Xiao, H., and D. G. Remick. 2005. Correction of perioperative hypothermia decreases experimental sepsis mortality by modulating the inflammatory response. Crit. Care Med. 33: 161-167.
38. Ertel, W., M. H. Morrison P. Wang, Z. F. Ba, A. Ayala, and I. H. Chaudry. 1991. The complex pattern of cytokines in sepsis association between prostaglandins, cachectin, and interleukins. Ann. Surg. 214: 141-148.
39. Salkowski, C. A., G. Detore, A. Franks, M. C. Falk, and S. N. Vogel. 1998. Pulmonary and hepatic gene expression following cecal ligation and puncture: monophosphoryl lipid A prophylaxis attenuates sepsis induced cytokine and chemokine expression and neutrophil infiltration. Infect. Immun. 66: 3569-3578.
40. Ashare, A., L. S. Powers, N. S. Butler, K. C. Doerschug, M. M. Monick, and G. W. Hunninghake. 2005. Anti-inflammatory, response is associated with mortality and severity of infection in sepsis. Am. J. Physiol. 288: L633-L640.
41. Gogos, C. A., E. Drosou, H. P. Bassaris, and A. Skoutelis. 2000. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 181: 176-180.
42. Neidhardt, R., M. Keel, U. Steckholzer, A. Safret, U. Ungethuem, O. Trentz, and W. Ertel. 1997. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J. Trauma 42: 863-870.
43. Turnbull, I. R., P. Javadi, T. G. Buchman, R. S. Hotchkiss, I. E. Karl, and C. M. Coopersmith. 2004. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 21: 121-125.
44. Bone, R. C., R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein, W. A. Knaus, R. M. Schein, and W. J. Sibbald. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655.
45. Wichterman, K. A., A. E. Baue, and I. H. Chaudry. 1980. Sepsis and septic shock-a review of laboratory models and a proposal. J. Surg. Res. 29: 189-201.
46. Copeland, S., H. S. Warren, S. F. Lowry, S. E. Calvano, and D. Remick. 2005. Acute inflammatory response to endotoxin in mice and humans. Clin. Diagn. Lab. Immunol. 12: 60-67.
47. Remick, D. G., D. E. Newcomb, G. L. Bolgos, and D. R. Call. 2000. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13: 110-116.
48. Harbarth, S., K. Holeckova, C. Froidevaux, D. Pittet, B. Ricou, G. E. Grau, L. Vadas, J. Pugin, and Geneva Sepsis Network. 2001. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am. J. Respir. Crit. Care Med. 164: 396-402.
49. Bonville, D. A., T. S. Parker, D. M. Levine, B. R. Gordon, L. J. Hydo, S. R. Eachempati, and P. S. Barie. 2004. The relationships of hypocholesterolemia to cytokine concentrations and mortality in critically ill patients with systemic inflammatory response syndrome. Surg. Infect. 5: 39-49.
50. Ertel, W., J. P. Kremer, J. Kenney, U. Steckholzer, D. Jarrar, O. Trentz, and F. W. Schildberg. 1995. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85: 1341-1347.
51. Heagy, W., K. Nieman, C. Hansen, M. Cohen, D. Danielson, and M. A. West. 2003. Lower levels of whole blood LPS-stimulated cytokine release are associated with poorer clinical outcomes in surgical ICU patients. Surg. Infect. 4: 171-180.
52. Ayala, A., Z. K. Deol, D. L. Lehman, C. D. Herdon, and I. H. Chaudry. 1994. Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-γ release while increasing IL-4/IL-10 production. J. Surg. Res. 56: 579-585.
53. Ayala, A., P. J. O'Neill, S. A. Uebele, C. D. Herdon, and I. H. Chaudry. 1997. Mechanism of splenic immunosuppression during sepsis: key role of Kupffer cell mediators. J. Trauma 42: 882-888.
54. Ayala, A., M. A. Urbanich, C. D. Herdon, and I. H. Chaudry. 1996. Is sepsis-induced apoptosis associated with macrophage dysfunction? J. Trauma 40: 568-573.
55. Newton, S., Y. Ding, C. S. Chung, Y. Chen, J. L. Lomas-Neira, and A. Ayala. 2004. Sepsis-induced changes in macrophage co-stimulatory molecule expression: CD86 as a regulator of anti-inflammatory IL-10 response. Surg. Infect. 5: 375-383.
56. Tschaikowsky, K., M. Hedwig-Geissing, A. Schiele, F. Bremer, M. Schywalsky, and J. Schuttler. 2002. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin: C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit. Care Med. 30: 1015-1023.
57. Levy, M. M., M. P. Fink, J. C. Marshall, E. Abraham, D. Angus, D. Cook, J. Cohen, S. M. Opal, J. L. Vincent, and G. Ramsay. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31: 1250-1256.
58. Abraham, E., P. F. Laterre, J. Garbino, S. Pingleton, T. Butler, T. Dugernier, B. Margolis, K. Kudsk, W. Zimmerli, P. Anderson, et al. 2001. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit. Care Med. 29: 503-510.
59. Dollner, H., L. Vatten, and R. Austgulen. 2001. Early diagnostic markers for neonatal sepsis: comparing C-reactive protein, interleukin-6, soluble, tumour necrosis factor receptors and soluble adhesion molecules. J. Clin. Epidemiol. 54: 1251-1257.
60. Pilz, G., P. Fraunberger, R. Appel, E. Kreuzer, K. Werdan, A. Walli, and D. Seidel. 1996. Early prediction of outcome in score-identified, postcardiac surgical patients at high risk for sepsis, using soluble tumor necrosis factor receptor-p55 concentrations. Crit. Care Med. 24: 596-600.
61. Lekkou, A., M. Karakantza, A. Mouzaki, F. Kalfarentzos, and C. A. Gogos. 2004. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin. Diagn. Lab. Immunol. 11: 161-167.